United States (National)
Not enough data
Phalguni Deswal's coverage is heavily focused on the Healthcare & Pharmaceutical industry, particularly around announcements and data citations related to neurology, MedTech, pharmaceuticals, clinical trials, and healthcare technology. Given this focus, she would likely be most responsive to pitches that offer in-depth insights into groundbreaking developments within these areas.
She seems receptive to detailed data-driven analysis and may also welcome commentary from experts who can provide valuable context or industry-specific knowledge. Pitches offering unique perspectives on acquisitions, FDA reviews of medications or medical devices could align well with her coverage.
Since there is no specified geographic focus for Phalguni's work, it suggests a global perspective on healthcare and pharmaceutical topics may be relevant when reaching out to her.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Phalguni Deswal
CMR Surgical is entering the US surgical robotics market with a counter-intuitive playbook: complement rather than displace incumbents, lead on portability, and build a data moat through an NVIDIA partnership — while Intuitive still owns the room.
By: Phalguni Deswal
Medtech financing looked like it rebounded in H1 2026 — but the money went to AI drug discovery, not devices. Strip out biotech and pure medtech funding fell to $3.54bn, a six-year low, as venture collapsed, mega-rounds vanished and the IPO window stayed shut.
By: Phalguni
Solventum will separate from its $1.4bn Health Information Systems unit via spin-off, sale or merger, leaving a MedSurg-and-dental medtech company as its 3M split ends. A Q2 beat and Acera's strong start fed a full guidance raise.
By: Phalguni Deswal
The EU PPWR separates packaging compliance into two distinct roles — manufacturer and producer — with very different obligations. Conflating them is the most common error lawyers see, and it can mean absorbing EPR costs that were never yours to carry.
The advisory committee is the defining catalyst: GRAIL expects an FDA panel later this year and still eyes approval in early 2027. The review will center on Galleri's own data, but management is betting a favorable outcome sets the approval bar for the whole MCED field.
By: Phalguni Deswal
Olympus's Q1 FY2027 beat — revenue up 16%, adjusted operating margin up 640bps to 12.8% — was driven almost entirely by GI endoscopy and a leaner cost base, but an unresolved FDA warning letter, US import alert and a 17% China decline kept management from touching full-year guidance.
A new Bain report says Asia-Pacific has shifted from medtech's factory floor to a genuine innovation source — 36% of global device research, two-thirds of patent filings, 30% of FDA 510(k) clearances. But a <5% share of FDA De Novo authorizations shows how far the region still has to climb.
By: Phalguni Deswal
UNITY surgical systems, PanOptix Pro and a fast-ramping dry-eye franchise drove 7% constant-currency growth in the second quarter — even as Alcon took a $402m charge to discontinue its PowerVision accommodating lens programs and struck a light-adjustable IOL collaboration with RxSight.
By: Phalguni Deswal
Regulatory approval is only the beginning. Reimbursement, talent, IP, funding and infrastructure gaps are preventing Asia-Pacific medtechs from scaling globally. Here's what founders, MNCs and governments must do differently.
The PPWR bolts new packaging-labeling duties onto device packs already governed by the MDR and IVDR. Manufacturer identification kicks in from Aug. 12; harmonized material and sorting pictograms follow from 2028. Experts told Medtech Insight the hardest part is finding room for it all.
